Ionis share price
Web22 feb. 2024 · R&D revenue for 2024 included $112 million from Biogen for advancing several neurology disease programs, $77 million from AstraZeneca for its share of the global Phase 3 development costs for eplontersen and $64 million from Roche for licensing and advancing IONIS-FB-L Rx, among other partner payments. WebIn May 2016, Ionis licensed the rights to the drug to Kastle Therapeutics for $15 million upfront with another $10 million due in May 2024, up to $70 million in milestones based …
Ionis share price
Did you know?
Web12 apr. 2024 · IONS - Ionis Pharmaceuticals Inc Stock Price Quote - NASDAQ Morningstar Ionis Pharmaceuticals Inc IONS Stock Quote Morningstar Rating Rating … Web9 nov. 2024 · For the nine months ended September 30, 2024 Ionis recognized $1.4 million and $1.5 million of medical affairs expenses and commercialization expenses for eplontersen, respectively, net of cost-share funding from AstraZeneca. Ionis expects its medical affairs and commercialization expenses to increase as this collaboration …
Web1 apr. 2024 · IONIS PHARMACEUTICALS INC stock price forecast for further price development up to 0. ... 1 day) and price target of 36.61 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) IONIS PHARMACEUTICALS INC share price prediction for 2024-05-26 with daily closed price projections Key Facts Symbol IONS ISIN … Web22 feb. 2024 · R&D revenue for 2024 included $112 million from Biogen for advancing several neurology disease programs, $77 million from AstraZeneca for its share of the …
Web8 feb. 2024 · The shares started trading below the issue price through the first day of trading on the Frankfurt Stock Exchange and closed at 17.54 euros. The initial public …
WebStock analysis for Ionis Pharmaceuticals Inc (IONS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Web26 jul. 2024 · To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma. Ionis' Forward-looking Statement. This press release includes forward-looking statements regarding Ionis’ business and the therapeutic and commercial potential of Ionis' technologies, IONIS-MAPTRx/BIIB080 and other products in development. csc6nd02c3wfWeb12 apr. 2024 · About IONS. Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal … csc6nb01g2wfWeb24 mrt. 2024 · After this action, Monia Brett P now owns 145,305 shares of Ionis Pharmaceuticals Inc., valued at $1,003,153 using the latest closing price. HOUGEN ELIZABETH L, the EVP, Finance & CFO of Ionis Pharmaceuticals Inc., sale 2,079 shares at $40.59 during a trade that took place back on Feb 06, which means that HOUGEN … csc6tc32wfr强制解绑Web10 apr. 2024 · Summary of all time highs, changes and price drops for Ionis Pharmaceuticals; Historical stock prices; Current Share Price: US$37.27: 52 Week High: … csc6hc3b1wfr说明书Web25 mrt. 2024 · With a net profit of EUR 589 million in 2024, Borealis achieved a strong financial result and demonstrated its resilience in an extraordinary year: a global market reeling from the effects of the coronavirus pandemic and an unprecedented slump in the price of oil in the first months of the year. Yet polyolefin sales volume growth for Borealis ... cs c6h 31wfrWeb22 feb. 2024 · For the year ended December 31, 2024 Ionis recognized $2.0 million and $2.6 million of medical affairs expenses and commercialization expenses for eplontersen, respectively, net of cost-share funding from AstraZeneca. Ionis expects its medical affairs and commercialization expenses to increase as this collaboration progresses. csc-5s 取付Web19 mrt. 2024 · Ionis' sales price and market cap have been guilty of long-term loitering. Despite its proven ability to earn growing revenues and its unmatched pipeline validated by some 10 partnership deals... csc6125ds2a2ax